28 November 2022
EMA/PRAC/853738/2022 Corr[1] [2]
Human Medicines Division

Pharmacovigilance Risk Assessment Committee (PRAC)

Draft agenda for the meeting on 28 November - 01 December 2022

Chair: Sabine Straus – Vice-Chair: Martin Huber

28 November 2022, 13:00 – 19:30, 1C / via teleconference

29 November 2022, 08:30 – 19:30, 1C / via teleconference

30 November 2022, 08:30 – 19:30, 1C / via teleconference

01 December 2022, 08:30 – 16:00, 1C / via teleconference

Organisational, regulatory and methodological matters (ORGAM)

15 December 2022, 09:00 – 12:00, via teleconference

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to

[1] 29 November 2022 - Cetrorelix - CETROTIDE (CAP); NAP - PSUSA/00000633/202204 procedure moved from section 6.1 to section 6.2
[2] 08 December 2022 – Correction of procedure numbers for Lemtrada (alemtuzumab) – changes in sections 7.1 and 7.6

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

documents (EMA/127362/2006 Rev.1).

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 28 November – 01 December 2022. See December 2022 PRAC minutes (to be published post January 2022 PRAC meeting).

1.2. Agenda of the meeting on 28 November - 01 December 2022

Action: For adoption

1.3. Minutes of the previous meeting on 24-27 October 2022

Action: For adoption

2. EU referral procedures for safety reasons: urgent EU procedures

2.1. Newly triggered procedures

None

2.2. Ongoing procedures

None

2.3. Procedures for finalisation

2.3.1. Pholcodine (NAP); pholcodine, biclotymol, chlorphenamine (NAP); pholcodine, chlorphenamine (NAP); pholcodine, chlorphenamine, ephedrine (NAP); pholcodine, diphenhydramine (NAP); pholcodine, dextromethorphan, paracetamol (NAP); pholcodine, diphenhydramine, paracetamol, pseudoephedrine (NAP); pholcodine, guaiacol (NAP); pholcodine, paracetamol, pseudoephedrine (NAP) - EMEA/H/A-107i/1521

Applicant(s): various

PRAC Rapporteur: Željana Margan Koletić; PRAC Co-rapporteur: Lina Seibokiene

Scope: Review of the benefit-risk balance following notification by France of a referral under Article 107i of Directive 2001/83/EC, based on pharmacovigilance data

Action: For adoption of a recommendation to CMDh

3. EU referral procedures for safety reasons: other EU referral procedures

3.1. Newly triggered procedures

None

3.2. Ongoing procedures

3.2.1. Topiramate (NAP); topiramate, phentermine (NAP) - EMEA/H/A-31/1520

Applicant(s): various

PRAC Rapporteur: Ulla Wändel Liminga; PRAC Co-rapporteur: Martin Huber

Scope: Review of the benefit-risk balance following notification by France of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

Action: For adoption of a list of outstanding issues (LoOI)

3.3. Procedures for finalisation

None

3.4. Re-examination procedures[3]

None

3.5. Others

None

4. Signals assessment and prioritisation[4]

4.1. New signals detected from EU spontaneous reporting systems

4.1.1. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP)

Applicant: AstraZeneca AB

PRAC Rapporteur: Jean-Michel Dogné

[3] Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC
[4] Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required

Scope: Signal of pemphigus and pemphigoid

Action: For adoption of PRAC recommendation

EPITT 19858 – New signal

Lead Member State(s): BE

4.1.2. Elasomeran – SPIKEVAX (CAP)

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Signal of pemphigus and pemphigoid

Action: For adoption of PRAC recommendation

EPITT 19860 – New signal

Lead Member State(s): DK

4.1.3. Evolocumab – REPATHA (CAP)

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Kimmo Jaakkola

Scope: Signal of weight increase and abnormal weight gain

Action: For adoption of PRAC recommendation

EPITT 19867 – New signal

Lead Member State(s): FI

4.1.4. Tozinameran – COMIRNATY (CAP)

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Signal of pemphigus and pemphigoid

Action: For adoption of PRAC recommendation

EPITT 19859 – New signal

Lead Member State(s): NL

4.2. New signals detected from other sources

None

4.3. Signals follow-up and prioritisation

4.3.1. Cetuximab – ERBITUX (CAP) - EMEA/H/C/000558/SDA/054

Applicant: Merck Europe B.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Signal of nephrotic syndrome

Action: For adoption of PRAC recommendation

EPITT 19819 – Follow-up to July 2022

4.3.2. Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) (NAP); diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) (NAP)

Applicant(s): various

PRAC Rapporteur: Anette Kirstine Stark

Scope: Signal of immune thrombocytopenia

Action: For adoption of PRAC recommendation

EPITT: 19831 – Follow-up to July 2022

4.4. Variation procedure(s) resulting from signal evaluation

None

5. Risk management plans (RMPs)

5.1. Medicines in the pre-authorisation phase

5.1.1. Eculizumab - EMEA/H/C/005652

Scope: Treatment of paroxysmal nocturnal haemoglobinuria

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.2. Ivosidenib - EMEA/H/C/005936, Orphan

Applicant: Les Laboratoires Servier

Scope: Treatment of acute myeloid leukaemia and treatment of metastatic cholangiocarcinoma

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.3. Ivosidenib - EMEA/H/C/006174, Orphan

Applicant: Les Laboratoires Servier

Scope: Treatment of acute myeloid leukaemia

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.4. Lenadogene nolparvovec - EMEA/H/C/005047, Orphan

Applicant: GenSight Biologics S.A., ATMP[5]

Scope: Treatment of vision loss due to Leber Hereditary Optic Neuropathy (LHON)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.1.5. Molnupiravir – EMEA/H/C/005789

Scope: Treatment of coronavirus disease 2019 (COVID-19)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.6. Niraparib, abiraterone acetate - EMEA/H/C/005932

Scope: Treatment of adult patients with prostate cancer

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.7. Raltegravir potassium - EMEA/H/C/005813

Scope: Treatment of human immunodeficiency virus (HIV-1)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.8. Trastuzumab - EMEA/H/C/005769

Scope: Treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.2. Medicines in the post-authorisation phase – PRAC-led procedures

5.2.1. Aripiprazole - ARIPIPRAZOLE MYLAN PHARMA (CAP); NAP - EMEA/H/C/003803/WS2306/0020

Applicant(s): Mylan Pharmaceuticals Limited

PRAC Rapporteur: Ana Sofia Diniz Martins

[5] Advanced therapy medicinal product

Scope: Submission of an updated RMP (version 6.0) to align the safety concerns in the RMP with the reference product. In addition nationally authorised product have been included in the RMP for the company

Action: For adoption of PRAC Assessment Report

5.2.2. Coronavirus (COVID-19) vaccine (Ad26.COV2-S, recombinant) - JCOVDEN (CAP) - EMEA/H/C/005737/II/0065

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Submission of an updated RMP version 5.1 in order to update the clinical exposure and risk sections

Action: For adoption of PRAC Assessment Report

5.2.3. Coronavirus (COVID-19) vaccine (recombinant, adjuvanted) - NUVAXOVID (CAP) - EMEA/H/C/005808/II/0028

Applicant: Novavax CZ, a.s.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Submission of an updated RMP version 2.1 due to reclassification of myocarditis and/or pericarditis from important potential risk to important identified risk

Action: For adoption of PRAC Assessment Report

5.2.4. Estrogens conjugated, bazedoxifene - DUAVIVE (CAP) - EMEA/H/C/002314/II/0032

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Martin Huber

Scope: Submission of an updated RMP version 3.2 in order to reflect the updated study milestones and completion of the PASS of CE/BZA in the United States (US PASS, Study B2311060) previously assessed as part of II/0030 (MEA 002.15), as well as to update the post marketing data with the data lock point of 31 October 2021

Action: For adoption of PRAC Assessment Report

5.2.5. Filgrastim - FILGRASTIM HEXAL (CAP) - EMEA/H/C/000918/WS2369/0066; ZARZIO (CAP) - EMEA/H/C/000917/WS2369/0067

Applicant: Sandoz GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Submission of an updated RMP version 13.0 to reduce the list of safety concerns and remove risks which are well characterised and already included in the product information, following PSUR single assessment (PSUSA) procedure (PSUSA/00001391/202109) concluded in May 2022. Additionally, the due date of the final study report EP06-501 (MEA007) has been updated

Action: For adoption of PRAC Assessment Report

5.2.6. Micafungin - MYCAMINE (CAP) - EMEA/H/C/000734/II/0047

Applicant: Astellas Pharma Europe B.V.

PRAC Rapporteur: Martin Huber

Scope: Update of Annex II and the RMP to version 23.0 to include the results of the non-interventional PASS 9463-PV-0002: effectiveness check of the prescriber checklist for Mycamine (micafungin)

Action: For adoption of PRAC Assessment Report

5.2.7. Palivizumab - SYNAGIS (CAP) - EMEA/H/C/000257/II/0131

Applicant: AstraZeneca AB

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Submission of an updated RMP version 2.0 in order to remove from the list of safety concerns "Anaphylaxis, Anaphylactic shock, and Hypersensitivity" and "Medication error of mixing lyophilised and liquid palivizumab before injection". In addition, the MAH took the opportunity to apply the revised template

Action: For adoption of PRAC Assessment Report

5.2.8. Ropeginterferon alfa-2b - BESREMI (CAP) - EMEA/H/C/004128/II/0025

Applicant: AOP Orphan Pharmaceuticals GmbH

PRAC Rapporteur: Inês Ribeiro-Vaz

Scope: Submission of an updated RMP version 1.1 for Besremi to revise safety concerns according to GVP Module V Rev.2

Action: For adoption of PRAC Assessment Report

5.2.9. Tobramycin - TOBI PODHALER (CAP) - EMEA/H/C/002155/II/0053, Orphan

Applicant: Mylan IRE Healthcare Limited

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Submission of an updated RMP version 8.0 following PSUR single assessment (PSUSA) procedure (PSUSA/00009315/202106) concluded in February 2022 in order to update it based on the guidance provided in the GVP and to remove the safety concerns as well as to reflect the finalisation of study CTBM100C2407 and the transfer of ownership

Action: For adoption of PRAC Assessment Report

5.3. Medicines in the post-authorisation phase – CHMP-led procedures

5.3.1. Atidarsagene autotemcel - LIBMELDY (CAP) - EMEA/H/C/005321/II/0011/G, Orphan

Applicant: Orchard Therapeutics (Netherlands) B.V., ATMP[6]

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Grouped variations consisting of: 1) update of sections 4.2, 4.4, 4.5, 4.8, and 5.1 of the SmPC in order to remove the option of using bone marrow (BM) as a cellular source for the manufacture of Libmeldy, as a result of an evolution of clinical practices and also to rationalise the manufacture of this highly complex medicinal product; the package leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to remove ANX/002 from the Annex II and to introduce minor editorial changes to the product information. The RMP version 1.3 has also been submitted; 2) other quality related variations

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.3.2. Baricitinib - OLUMIANT (CAP) - EMEA/H/C/004085/II/0028

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Extension of indication to include treatment of coronavirus disease 2019 (COVID-19) in hospitalised adult and paediatric patients aged 10 years and older who require low-flow oxygen or non-invasive ventilation/high flow oxygen. As a consequence, sections 4.1, 4.2, 4.4, 4.6, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. Annex II, the package leaflet and the RMP (version 11.1) are updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.3. Bimekizumab - BIMZELX (CAP) - EMEA/H/C/005316/II/0010

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Extension of indication to include treatment of adults with active axial spondyloarthritis (axSpA), including non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS, radiographic axial spondyloarthritis), based on interim results from two interventional and controlled phase III clinical studies: AS0010 (BE MOBILE 1) and AS0011 (BE MOBILE 2), which provide evidence of the efficacy and safety of bimekizumab in axSpA (nr-axSpA and AS), both compared to placebo treatment. Further supportive data is provided by the results of a phase 2a exploratory study (AS0013), a phase 2b, dose-ranging study (AS0008) and its ongoing follow-on phase 2b open-label extension (OLE) study (AS0009). As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 1.2 of the RMP has also been submitted. Furthermore, the product information is brought in line with the latest QRD

[6] Advanced therapy medicinal product

template version 10.2 rev.1

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.4. Bimekizumab - BIMZELX (CAP) - EMEA/H/C/005316/II/0011

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Extension of indication to include treatment of active psoriatic arthritis in adults patients who have had an inadequate response or who have been intolerant to one or more DMARDs for Bimzelx (bimekizumab), based on interim results of a Phase III study in biological DMARD naïve study participants (PA0010; BE OPTIMAL) and the final results of the Phase III study in study participants who are inadequate responders (inadequate response or intolerant) to ≤2 prior TNF inhibitors (PA0011; BE COMPLETE). Both Phase III studies are interventional studies aimed to evaluate the efficacy and safety of bimekizumab. For PA0010, the Initial Treatment Period was placebo- and no inferential active reference (adalimumab)-controlled, while PA0011 was placebo-controlled. Further supportive data comprise the results of a Phase 1 study (PA0007), a Phase 2b dose-finding study (PA0008) and a Phase 2 open label extension study (PA0009). A Phase 3 open-label extension study is currently ongoing (PA0012). As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 to the SmPC have been updated. The package leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. Furthermore, the product information is brought in line with the latest QRD template version 10.2 rev.1. As part of the application the MAH is requesting a 1-year extension of the market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.5. Caplacizumab - CABLIVI (CAP) - EMEA/H/C/004426/II/0040, Orphan

Applicant: Ablynx NV

PRAC Rapporteur: Jan Neuhauser

Scope: Update of sections 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC in order to update information on long-term efficacy and safety based on final results from study ALX0681-C302/LTS16371 - Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES), listed as a category 3 study in the RMP. The Post-HERCULES study was a Phase III, 36-month follow-up study from HERCULES (parent study) to evaluate the long-term outcomes as well as the safety and efficacy of repeat use of caplacizumab in patients who experienced a recurrence of acquired thrombotic thrombocytopenic purpura (aTTP). The RMP version 3.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.6. Ciltacabtagene autoleucel - CARVYKTI (CAP) - EMEA/H/C/005095/II/0003, Orphan

Applicant: Janssen-Cilag International NV, ATMP[7]

[7] Advanced therapy medicinal product

PRAC Rapporteur: Jo Robays

Scope: Update of sections 4.4 and 4.8 of the SmPC in order to update the existing warnings on cytokine release syndrome (CRS), neurologic toxicities and grading of related events and to update the list of adverse drug reactions (ADRs) based on previously reviewed data from studies MMY2001 and MMY2003, and an additional internal characterisation of neurotoxicity risk. The package leaflet is updated accordingly. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.3.7. Ciltacabtagene autoleucel - CARVYKTI (CAP) - EMEA/H/C/005095/II/0004/G, Orphan

Applicant: Janssen-Cilag International NV, ATMP[8]

PRAC Rapporteur: Jo Robays

Scope: Grouped variations consisting of: 1) update of section 4.4 of the SmPC in order to add a new warning on increased risk of severe/fatal COVID-19 infections following Covid-19 signal evaluation from the ongoing study 68284528MMY3002 (CARTITUDE-4) based on a cumulative review of all clinical trials, registries and literature; 2) update of section 4.4 of the SmPC in order to add a new warning on risk of severe bleeding in the context of hemophagocytic lymphohistiocytosis syndrome (HLH) following a signal evaluation from the ongoing study 68284528MMY3002 (CARTITUDE-4) based on cumulative review of all clinical trials, registries and literature. The package leaflet is updated accordingly. The RMP version 2.2 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.3.8. Concentrate of proteolytic enzymes enriched in bromelain - NEXOBRID (CAP) - EMEA/H/C/002246/II/0058, Orphan

Applicant: MediWound Germany GmbH

PRAC Rapporteur: Martin Huber

Scope: Extension of current indication for removal of eschar in adults with deep partial- and full-thickness thermal burns to the paediatric population for NexoBrid based on interim results from study MW2012-01-01 (CIDS study), listed as Study MW2012-01-01 is a 3-stage, multi-centre, multi-national, randomised, controlled, open label, 2 arm study aiming to demonstrate the superiority of NexoBrid treatment over SOC treatment in paediatric patients (aged 0 to 18 years) with deep partial thickness (DPT) and full thickness (FT) thermal burns of 1% to 30% of total body surface area (TBSA). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet is updated accordingly. Version 9 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

[8] Advanced therapy medicinal product

5.3.9. Darolutamide - NUBEQA (CAP) - EMEA/H/C/004790/II/0009

Applicant: Bayer AG

PRAC Rapporteur: Jan Neuhauser

Scope: Extension of indication to include treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel, based on final results from study 17777 (ARASENS): a randomised, double-blind, placebo-controlled phase 3 study designed to demonstrate the superiority of darolutamide in combination with docetaxel over placebo in combination with docetaxel in overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). As a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. The package leaflet and the RMP (version 2.1) are updated in accordance. The MAH also requested one additional year of market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.10. Darolutamide - NUBEQA (CAP) - EMEA/H/C/004790/II/0012

Applicant: Bayer AG

PRAC Rapporteur: Jan Neuhauser

Scope: Submission of the final report of carcinogenicity study T104877-7 listed as a category 3 study in the RMP. This is a non-clinical study to assess the carcinogenic potential in mice. The study evaluates the effects of daily oral administration of darolutamide for a period of 6 months in tg-rasH2 transgenic mouse model. The updated RMP version 3.1 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.11. Dolutegravir, abacavir, amivudine - TRIUMEQ (CAP) - EMEA/H/C/002754/X/0101/G

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: Grouped application consisting of: 1) extension application to introduce a new pharmaceutical form associated with a new strength (5 mg/60 mg/30 mg dispersible tablet). The new presentation is indicated for the treatment of human immunodeficiency virus (HIV) infected children weighing at least 14 kg to less than 25 kg; 2) extension of indication to include treatment of human immunodeficiency virus (HIV) infected children weighing at least 25 kg for the already approved film-coated tablets. As a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC are updated. The package leaflet and labelling are updated in accordance. The RMP (version 19) is updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.12. Dostarlimab - JEMPERLI (CAP) - EMEA/H/C/005204/II/0013

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Inês Ribeiro-Vaz

Scope: Update of section 5.1 of the SmPC in order to update efficacy and safety information based on interim results from study 4010-01-001 (GARNET) listed as a specific obligation in the Annex II; This is a single-arm, open-label, phase I trial of intravenous dostarlimab in advanced solid tumours. In addition, the MAH took the opportunity to update section E of Annex II. The RMP version 1.2 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.13. Durvalumab - IMFINZI (CAP) - EMEA/H/C/004771/II/0041

Applicant: AstraZeneca AB

PRAC Rapporteur: David Olsen

Scope: Extension of indication to include first-line treatment, with durvalumab in combination with tremelimumab and platinum-based chemotherapy, of adults with metastatic non-small-cell lung carcinoma (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations, based on final results from study D419MC00004 (POSEIDON): a phase 3, randomised, multicentre, open-label, comparative global study to determine the efficacy and safety of tremelimumab and durvalumab or durvalumab in combination with platinum based chemotherapy for first-line treatment in patients with metastatic NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet. Furthermore, the product information is brought in line with the latest quality review of documents (QRD) template (version 10.2). The RMP (version 5.1) is updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.14. Durvalumab - IMFINZI (CAP) - EMEA/H/C/004771/II/0045

Applicant: AstraZeneca AB

PRAC Rapporteur: David Olsen

Scope: Extension of indication to include IMFINZI in combination with tremelimumab for the treatment of adults with unresectable hepatocellular carcinoma (uHCC), based on final results from Study D419CC00002 (HIMALAYA): a randomised, open-label, multi-center phase III study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and package leaflet. Version 6.1 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.15. Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/II/0027

Applicant: Roche Registration GmbH

PRAC Rapporteur: Amelia Cupelli

Scope: Extension of indication to include treatment of adult and paediatric patients with

haemophilia A without factor VIII (FVIII) inhibitors who have mild or moderate disease for whom prophylaxis is clinically indicated. Consequently, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC are updated. In addition, section 4.2 of the SmPC is updated to make clearer that the maintenance dose for Hemlibra (emicizumab) applies from week 5 of dosing. The package leaflet and the RMP (version 4.0) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.16. Evolocumab - REPATHA (CAP) - EMEA/H/C/003766/II/0061

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Kimmo Jaakkola

Scope: Update of sections 4.8 and 5.1 of the SmPC in order to update safety information and include long-term safety and efficacy data based on final results from Study 20130295 and Study 20160250 listed as category 3 studies in the RMP; these are phase 3b, multicenter, open-label extension (OLE) studies designed to assess the long-term safety of evolocumab in subjects who completed the FOURIER study (Study 20110118). The RMP version 8.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.17. Granisetron - SANCUSO (CAP) - EMEA/H/C/002296/II/0061

Applicant: Kyowa Kirin Holdings B.V.

PRAC Rapporteur: Rugile Pilviniene

Scope: Update of sections 4.4, 4.6, 4.7, 4.8, 4.10 and 5.3 of the SmPC in order to add 'Serotonin syndrome' and 'Application site Reactions' to the list of adverse drug reactions (ADRs) with frequency 'unknown' as well as 'Application site Irritation' with frequency 'uncommon' based on post-marketing data and literature. The MAH also proposes to update sections 4.4 and 4.5 of the SmPC to add drug-drug interaction information with buprenorphine/opioids and serotonergic medicinal products based on post-marketing data and literature. The package leaflet has been updated accordingly. The RMP version 5 has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes in the SmPC

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.18. Ipilimumab - YERVOY (CAP) - EMEA/H/C/002213/II/0100

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include in combination with nivolumab the treatment of adolescents (12 years of age and older) for advanced (unresectable or metastatic) melanoma, based on the pivotal study CA209070; this is a multicentre, open-label, single arm, phase 1/2 trial of nivolumab +/- ipilimumab in children, adolescents and young adults with recurrent or refractory solid tumours or lymphomas. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 38.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.19. Meningococcal group A, C, W-135 and Y conjugate vaccine - MENQUADFI (CAP) - EMEA/H/C/005084/II/0018/G

Applicant: Sanofi Pasteur

PRAC Rapporteur: Jean-Michel Dogné

Scope: Update of sections 4.2, 4.5, 4.8 and 5.1 of the SmPC in order to add long term antibody persistence at least 3 years after primary vaccination, immunogenicity and safety of a booster dose of MenQuadfi in adolescents, adults, and older adults, as well as co-administration data with meningococcal serogroup B vaccine in adolescents and adults, in order to fulfil ANX/002 and ANX/003 based on final results from studies MET59 and MEQ00066, respectively, listed as specific obligations in the Annex II. MET59 is a phase 3b, open-label, partially randomised, parallel-group, active-controlled, multi-center study evaluating the immunogenicity and safety of a booster dose of an investigational quadrivalent MenACYW conjugate vaccine in adolescents and adults, while MEQ00066 is a phase 3, two-stage, randomised, open-label, multi-center trial evaluating the safety and immunogenicity of a single dose of MenACYW conjugate vaccine at least 3 years following initial vaccination with either Menomune vaccine or MenACYW conjugate vaccine in older adults. The Annex II and package leaflet are updated accordingly. The RMP version 1.1 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.20. Nivolumab - OPDIVO (CAP) - EMEA/H/C/003985/II/0125/G

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Extension of indication to include adolescent patients aged 12 years and older in treatment of advanced (unresectable or metastatic) melanoma (nivolumab monotherapy), treatment of advanced (unresectable or metastatic) melanoma (nivolumab in combination with ipilimumab) and adjuvant treatment of melanoma (nivolumab monotherapy) for Opdivo, based on results from a nonclinical biomarker study (Expression of PD-L1 (CD274), and characterization of tumour infiltrating immune cells in tumours of paediatric origin), also based on results from a Phase 1/2 clinical study (CA209070, a phase 1/2 study of Nivolumab (Ind# 124729) in children, adolescents, and young adults with recurrent or refractory solid tumours as a single agent and in combination with Ipilimumab) and a modelling and simulation study. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The package leaflet is updated in accordance. Version 30.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.21. Ocrelizumab - OCREVUS (CAP) - EMEA/H/C/004043/II/0034/G

Applicant: Roche Registration GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Grouped variations consisting of: 1) submission of the final report from study BN29739 (VELOCE) listed as a category 3 study in the RMP. This is a phase 3b, multicentre, randomised, parallel-group, open-label study to evaluate the effectiveness of vaccinations in patients with relapsing forms of multiple sclerosis (RMS) undergoing treatment with ocrelizumab; 2) submission of the final report from studies MA30005 (CASTING) and MN30035 (CHORDS). These are prospective, multicentre, international, interventional, open-label phase 3b studies to assess the efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment. The RMP version 8.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.22. Olipudase alfa - XENPOZYME (CAP) - EMEA/H/C/004850/II/0001/G, Orphan

Applicant: Genzyme Europe BV

PRAC Rapporteur: Martin Huber

Scope: Grouped variations consisting of: 1) update sections 4.6 of the SmPC in order to include a recommendation to conduct a pregnancy test for women of childbearing potential (WOCP) prior to treatment initiation based on embryo-foetal study in mice (study TER0694). In addition, the MAH proposes an update of section 5.3 of the SmPC based on a re-calculation of exposure margins for the embryo-foetal study. MAH also proposes to align the SmPC with the updated CCDS; 2) update sections 4.6 and 5.3 of the SmPC in order to include data in lactating mice based on final results from study MSSM-1120 - Evaluation of Olipudase alfa Transfer Into Milk of Lactating Mice. The package leaflet is updated accordingly. The RMP version 2.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.23. Omalizumab - XOLAIR (CAP) - EMEA/H/C/000606/X/0115/G

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Mari Thorn

Scope: Extension application to add a new strength of 300 mg (150 mg/ml) for Xolair solution for injection grouped with quality type II, IB and IAIN variations. The RMP (version 17.0) is updated in accordance.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.24. Oritavancin - TENKASI (CAP) - EMEA/H/C/003785/II/0037

Applicant: Menarini International Operations Luxembourg S.A.

PRAC Rapporteur: Adam Przybylkowski

Scope: Extension of indication to include treatment of paediatric population, aged between 3 months and less than 18 years for Tenkasi (oritavancin) 400 mg based on interim results from study TMC-ORI-11-01; this is a multicenter, open-label, dose-finding study of oritavancin single dose infusion in paediatric subjects less than 18 years of age with suspected or confirmed bacterial infections. The purpose of this Phase 1 study is to evaluate the safety, tolerability and PK of oritavancin in paediatric subjects and determine the

optimal dose for a Phase 2 trial in paediatric subjects with acute bacterial skin structure infections (ABSSSI). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The package leaflet is updated in accordance. Version 5.0 of the RMP has also been submitted. In addition, MAH is also taking this opportunity to update the contact details of the local representatives in the package leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.2 rev 1

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.25. Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - APEXXNAR (CAP) - EMEA/H/C/005451/II/0006

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Jean-Michel Dogné

Scope: Update of sections 4.5, 4.8 and 5.1 of the SmPC based on final results from study B7471026 (listed as a category 3 study in the RMP): a phase III, randomised, double-blind trial to describe the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine when coadministered with a booster dose of BNT162b2 in adults 65 years of age and older. The package leaflet is updated accordingly. The RMP (version 2.1) has also been submitted to consolidate 2 RMP versions based on the outcome of current procedure and reflecting the changes in RMP version 2.0 (EMEA/H/C/005451/II/0006) and RMP version 1.1 (EMEA/H/C/005451/II/0002).

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.26. Ravulizumab - ULTOMIRIS (CAP) - EMEA/H/C/004954/II/0032

Applicant: Alexion Europe SAS

PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication to include the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin 4 (AQP4) antibody-positive, based on interim results from study ALXN1210-NMO-307; this is a phase 3, external placebo-controlled, open-label, multicenter study to evaluate the efficacy and safety of ravulizumab in adult patients with NMOSD. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 6.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.27. Riociguat - ADEMPAS (CAP) - EMEA/H/C/002737/II/0037

Applicant: Bayer AG

PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication to include treatment of pulmonary arterial hypertension (PAH) in paediatric patients aged 6 to less than 18 years of age with WHO Functional Class (FC) I to III in combination with endothelin receptor antagonists with or without prostanoids for Adempas (riociguat), based on results from pivotal study PATENT-CHILD (Study 15681);

this is a Phase III, Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with PAH; As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. The package Leaflet is updated in accordance. Version 8.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the package leaflet

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.28. Rucaparib - RUBRACA (CAP) - EMEA/H/C/004272/II/0036

Applicant: Clovis Oncology Ireland Limited

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Extension of indication to include maintenance treatment of adult patients with advanced (FIGO Stages III and IV) epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC) who are in response (complete or partial) to first-line platinum-based chemotherapy for RUBRACA, based on interim results from study CO-338-087 (ATHENA); this is a Phase III, randomised, double-blind, dual placebo controlled study of rucaparib as monotherapy and in combination with nivolumab in patients with newly diagnosed EOC, FTC, or PPC who have responded to their first-line treatment (surgery and platinum-based chemotherapy). As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 6.3 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.29. Rucaparib - RUBRACA (CAP) - EMEA/H/C/004272/II/0037

Applicant: Clovis Oncology Ireland Limited

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Update of sections 4.8 and 5.1 of the SmPC in order to update the efficacy and safety information and the list of adverse drug reactions (ADRs) based on the final results from study CO-338-014 (ARIEL 3) listed as a category 1 PAES in the Annex II; this is a phase 3, multicenter, randomised, double-blind, placebo-controlled study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer. The package leaflet is updated accordingly. The RMP version 6.4 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.30. Secukinumab - COSENTYX (CAP) - EMEA/H/C/003729/II/0090

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Monica Martinez Redondo

Scope: Extension of indication to include treatment of hidradenitis suppurativa (HS) for

COSENTYX, based on interim results from two phase III studies CAIN457M2301 (SUNSHINE) and CAIN457M2302 (SUNRISE). These studies are ongoing, multi-center, randomised, double-blind, placebo-controlled, parallel group phase 3 studies conducted to assess the short (16 weeks) and long-term (up to 52 weeks) efficacy and safety of two secukinumab dose regimens (Q2W or Q4W) compared to placebo in adult subjects with moderate to severe HS. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2. of the SmPC are updated. The package leaflet and the RMP (version 11) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.31. Semaglutide - WEGOVY (CAP) - EMEA/H/C/005422/II/0009

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Mari Thorn

Scope: Extension of indication to include treatment of adolescents for weight management for Wegovy based on final results from study NN9536-4451; this trial was conducted to assess the effect and safety of semaglutide in the paediatric population in order to address the unmet need for treatment of adolescents ages 12 to <18 years with obesity. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.2

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.32. Somatropin - OMNITROPE (CAP) - EMEA/H/C/000607/II/0073

Applicant: Sandoz GmbH

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Update of section 4.4 of the SmPC in order to add a new warning on scoliosis following in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00002772/202003) based on final results from study EP00-401 listed as a category 3 study in the RMP; this is a prospective, open-label, non-comparative, multicenter, Phase IV study to monitor the long-term safety and efficacy of Omnitrope in short children born small for gestational age (SGA), in particular the diabetogenic potential and immunogenicity of rhGH therapy. The package leaflet is updated accordingly. The RMP version 12.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.33. Tezepelumab - TEZSPIRE (CAP) - EMEA/H/C/005588/II/0001

Applicant: AstraZeneca AB

PRAC Rapporteur: Eva Jirsová

Scope: Addition of a new autoinjector (AI) presentation as an alternative method of administration, with consequential update to the product information. RMP (version 1.1) has been updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.34. Tocilizumab - ROACTEMRA (CAP) - EMEA/H/C/000955/II/0114

Applicant: Roche Registration GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Extension of indication to include treatment of new indication for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) for RoActemra, based on final results from the pivotal Phase III Study WA29767 (focuSSced) entitled, "A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis" and the supportive Phase II/III Study WA27788 (faSScinate) entitled, "A Phase II/III, Multicenter, Randomised, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis". As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 28 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.35. Trastuzumab deruxtecan - ENHERTU (CAP) - EMEA/H/C/005124/II/0022

Applicant: Daiichi Sankyo Europe GmbH

PRAC Rapporteur: Inês Ribeiro-Vaz

Scope: Extension of indication to include treatment of unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or withing 6 months of completing adjuvant chemotherapy. Patients with hormone receptor positive (HR+) breast cancer must additionally have received or be ineligible for endocrine therapy; for ENHERTU, based on final results from study DS8201-A-U303 (DESTINY-Breast04). This is a phase III, multicentre, randomised, open-label, active-controlled trial of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-antibody Drug Conjugate (ADC), versus treatment of physician's choice for HER2-low, unresectable and/or metastatic breast cancer subjects. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and the RMP (version 1.4) are updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update section 4.4 of the SmPC to update the dosing recommendation for corticosteroid treatment (e.g. prednisolone) with a daily dose

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

6. Periodic safety update reports (PSURs)

6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only

6.1.1. Acalabrutinib - CALQUENCE (CAP) - PSUSA/00010887/202204

Applicant: AstraZeneca AB

PRAC Rapporteur: Željana Margan Koletić

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.2. Andexanet alfa - ONDEXXYA (CAP) - PSUSA/00010764/202204

Applicant: AstraZeneca AB

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.3. Atezolizumab - TECENTRIQ (CAP) - PSUSA/00010644/202205

Applicant: Roche Registration GmbH

PRAC Rapporteur: Inês Ribeiro-Vaz

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.4. Axicabtagene ciloleucel - YESCARTA (CAP) - PSUSA/00010703/202204

Applicant: Kite Pharma EU B.V., ATMP[9]

PRAC Rapporteur: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CAT and CHMP

6.1.5. Azacitidine[10] - ONUREG (CAP) - PSUSA/00010935/202205

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

[9] Advanced therapy medicinal product
[10] Oral formulations only

Action: For adoption of recommendation to CHMP

6.1.6. Brigatinib - ALUNBRIG (CAP) - PSUSA/00010728/202204

Applicant: Takeda Pharma A/S

PRAC Rapporteur: Inês Ribeiro-Vaz

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.7. Bupivacaine[11] - EXPAREL LIPOSOMAL (CAP) - PSUSA/00010889/202204

Applicant: Pacira Ireland Limited

PRAC Rapporteur: Rhea Fitzgerald

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.8. Conestat alfa - RUCONEST (CAP) - PSUSA/00000873/202204 (with RMP)

Applicant: Pharming Group N.V

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.9. Crizanlizumab - ADAKVEO (CAP) - PSUSA/00010888/202205

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Jo Robays

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.10. Delamanid - DELTYBA (CAP) - PSUSA/00010213/202204

Applicant: Otsuka Novel Products GmbH

PRAC Rapporteur: Jo Robays

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.11. Diphtheria, tetanus, pertussis antigens (pertussis toxoid, filamentous haemagglutinin) (acellular, component), hepatitis b (rDNA[12]), poliomyelitis

[11] Liposomal formulations only
[12] Ribosomal deoxyribonucleic acid

(inactivated), haemophilus type b conjugate vaccines (adsorbed) - HEXACIMA (CAP); HEXYON (CAP) - PSUSA/00010091/202204

Applicant(s): Sanofi Pasteur (Hexacima), Sanofi Pasteur Europe (Hexyon)

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.12. Dolutegravir, rilpivirine - JULUCA (CAP) - PSUSA/00010689/202205

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Nathalie Gault

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.13. Dostarlimab - JEMPERLI (CAP) - PSUSA/00010931/202204

Applicant: GlaxoSmithKline (Ireland) Limited

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.14. Drospirenone, estetrol - DROVELIS (CAP); LYDISILKA (CAP) - PSUSA/00010938/202205

Applicant(s): Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.) (Drovelis), Estetra SRL (Lydisilka)

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.15. Durvalumab - IMFINZI (CAP) - PSUSA/00010723/202204

Applicant: AstraZeneca AB

PRAC Rapporteur: David Olsen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.16. Empagliflozin - JARDIANCE (CAP); empagliflozin, metformin - SYNJARDY (CAP) - PSUSA/00010388/202204

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.17. Entecavir - BARACLUDE (CAP) - PSUSA/00001224/202203

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.18. Erenumab - AIMOVIG (CAP) - PSUSA/00010699/202205

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Kirsti Villikka

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.19. Febuxostat - ADENURIC (CAP) - PSUSA/00001353/202204

Applicant: Menarini International Operations Luxembourg S.A.

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.20. Florbetapir (^{18}F) - AMYVID (CAP) - PSUSA/00010032/202204

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.21. Fostamatinib - TAVLESSE (CAP) - PSUSA/00010819/202204

Applicant: Instituto Grifols, S.A.

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.22. Givosiran - GIVLAARI (CAP) - PSUSA/00010839/202205

Applicant: Alnylam Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.23. Glycopyrronium bromide, formoterol - BEVESPI AEROSPHERE (CAP) - PSUSA/00010739/202204

Applicant: AstraZeneca AB

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.24. Hepatitis B surface antigen, CpG 1018 adjuvant - HEPLISAV B (CAP) - PSUSA/00010919/202205

Applicant: Dynavax GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.25. Insulin glargine - ABASAGLAR (CAP); LANTUS (CAP); SEMGLEE (CAP); TOUJEO (CAP) - PSUSA/00001751/202204

Applicant: Eli Lilly Nederland B.V. (Abasaglar), Sanofi-Aventis Deutschland GmbH (Lantus, Toujeo), Viatris Limited (Semglee)

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.26. Ivacaftor, tezacaftor, elexacaftor - KAFTRIO (CAP) - PSUSA/00010868/202204

Applicant: Vertex Pharmaceuticals (Ireland) Limited

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.27. Lumacaftor, ivacaftor - ORKAMBI (CAP) - PSUSA/00010455/202205

Applicant: Vertex Pharmaceuticals (Ireland) Limited

PRAC Rapporteur: Rhea Fitzgerald

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.28. Lumasiran - OXLUMO (CAP) - PSUSA/00010884/202205

Applicant: Alnylam Netherlands B.V.

PRAC Rapporteur: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.29. Mannitol[13] - BRONCHITOL (CAP) - PSUSA/00009226/202204

Applicant: Pharmaxis Europe Limited

PRAC Rapporteur: Nathalie Gault

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.30. Meningococcal group a, c, w135, y conjugate vaccine[14] - MENQUADFI (CAP); NIMENRIX (CAP) - PSUSA/00010044/202204

Applicant: Sanofi Pasteur (MenQuadfi), Pfizer Europe MA EEIG (Nimenrix)

PRAC Rapporteur: David Olsen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.31. Methylnaltrexone bromide - RELISTOR (CAP) - PSUSA/00002023/202203

Applicant: Bausch Health Ireland Limited

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.32. Nintedanib[15] - OFEV (CAP) - PSUSA/00010319/202204

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

[13] Indicated in cystic fibrosis
[14] Conjugated to tetanus toxoid carrier protein
[15] Respiratory indication(s) only

6.1.33. Oestrogens conjugated, bazedoxifene - DUAVIVE (CAP) - PSUSA/00010321/202204

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.34. Ozanimod - ZEPOSIA (CAP) - PSUSA/00010852/202205

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.35. Parathyroid hormone - NATPAR (CAP) - PSUSA/00010591/202204

Applicant: Takeda Pharmaceuticals International AG

PRAC Rapporteur: Rhea Fitzgerald

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.36. Pegcetacoplan - ASPAVELI (CAP) - PSUSA/00010974/202205

Applicant: Swedish Orphan Biovitrum AB (publ)

PRAC Rapporteur: Kimmo Jaakkola

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.37. Pemigatinib - PEMAZYRE (CAP) - PSUSA/00010923/202204

Applicant: Incyte Biosciences Distribution B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.38. Potassium citrate, potassium hydrogen carbonate - SIBNAYAL (CAP) - PSUSA/00010932/202204

Applicant: Advicenne

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.39. Ramucirumab - CYRAMZA (CAP) - PSUSA/00010323/202204

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.40. Recombinant vesicular stomatitis virus - Zaire ebolavirus vaccine (live) - ERVEBO (CAP) - PSUSA/00010834/202205

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.41. Remdesivir - VEKLURY (CAP) - PSUSA/00010840/202205

Applicant: Gilead Sciences Ireland UC

PRAC Rapporteur: Eva Jirsová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.42. Ripretinib - QINLOCK (CAP) - PSUSA/00010962/202205 (with RMP)

Applicant: Deciphera Pharmaceuticals (Netherlands) B.V.

PRAC Rapporteur: Željana Margan Koletić

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.43. Sacituzumab govitecan - TRODELVY (CAP) - PSUSA/00010959/202204

Applicant: Gilead Sciences Ireland UC

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.44. Selpercatinib - RETSEVMO (CAP) - PSUSA/00010917/202205

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.45. Siltuximab - SYLVANT (CAP) - PSUSA/00010254/202204

Applicant: EUSA Pharma (Netherlands) B.V.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.46. Somatrogon - NGENLA (CAP) - PSUSA/00010982/202204

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.47. Tafamidis - VYNDAQEL (CAP) - PSUSA/00002842/202205

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.48. Tixagevimab, cilgavimab - EVUSHELD (CAP) - PSUSA/00010992/202205

Applicant: AstraZeneca AB

PRAC Rapporteur: Kimmo Jaakkola

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.49. Tocilizumab - ROACTEMRA (CAP) - PSUSA/00002980/202204

Applicant: Roche Registration GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.50. Tucatinib - TUKYSA (CAP) - PSUSA/00010918/202204

Applicant: Seagen B.V.

PRAC Rapporteur: Jean-Michel Dogné

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.51. Volanesorsen - WAYLIVRA (CAP) - PSUSA/00010762/202205

Applicant: Akcea Therapeutics Ireland Limited

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.52. Zanubrutinib - BRUKINSA (CAP) - PSUSA/00010960/202205

Applicant: BeiGene Ireland Ltd

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)

6.2.1. Cetrorelix - CETROTIDE (CAP); NAP - PSUSA/00000633/202204

Applicant: Merck Europe B.V.

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.2. Efavirenz - STOCRIN (CAP); SUSTIVA (CAP); NAP - PSUSA/00001200/202204

Applicants: Bristol-Myers Squibb Pharma EEIG (Sustiva), Merck Sharp & Dohme B.V. (Stocrin), various

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.3. Hydrochlorothiazide, telmisartan - KINZALKOMB (CAP); MICARDISPLUS (CAP); PRITORPLUS (CAP); telmisartan - KINZALMONO (CAP); MICARDIS (CAP); PRITOR (CAP); NAP - PSUSA/00002882/202203

Applicants: Bayer AG (Kinzalkomb, Kinzalmono, Pritor, PritorPlus), Boehringer Ingelheim International GmbH (Micardis, MicardisPlus), various

PRAC Rapporteur: Amelia Cupelli

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.4. Olanzapine - ZALASTA (CAP); ZYPADHERA (CAP); ZYPREXA (CAP); ZYPREXA VELOTAB (CAP); NAP - PSUSA/00010540/202203

Applicants: Eli Lilly Nederland B.V. (Zypadhera, Zyprexa, Zyprexa Velotab), KRKA, d.d., Novo mesto (Zalasta), various

PRAC Rapporteur: Kimmo Jaakkola

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.5. Pramipexole - MIRAPEXIN (CAP); SIFROL (CAP); NAP - PSUSA/00002491/202204

Applicants: Boehringer Ingelheim International GmbH (Mirapexin, Sifrol), various

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.6. Zonisamide - ZONEGRAN (CAP); NAP - PSUSA/00003152/202203

Applicants: Amdipharm Limited (Zonegran), various

PRAC Rapporteur: Ronan Grimes

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.3. PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only

6.3.1. Amlodipine besilate, hydrochlorothiazide, olmesartan medoxomil (NAP) - PSUSA/00002210/202204

Applicant(s): various

PRAC Lead: Jana Lukačišinová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.2. Amlodipine, candesartan (NAP) - PSUSA/00010191/202204

Applicant(s): various

PRAC Lead: Eva Jirsová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.3. Amlodipine, olmesartan (NAP) - PSUSA/00002208/202204

Applicant(s): various

PRAC Lead: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.4. Bleomycin (NAP) - PSUSA/00000422/202203

Applicant(s): various

PRAC Lead: Marie Louise Schougaard Christiansen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.5. Candesartan (NAP); candesartan, hydrochlorothiazide (NAP) - PSUSA/00000527/202204

Applicant(s): various

PRAC Lead: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.6. Carvedilol (NAP) - PSUSA/00000575/202204

Applicant(s): various

PRAC Lead: Kimmo Jaakkola

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.7. Carvedilol, ivabradine (NAP) - PSUSA/00010883/202204

Applicant(s): various

PRAC Lead: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.8. Cefuroxime axetil (NAP) - PSUSA/00009099/202204

Applicant(s): various

PRAC Lead: Maia Uusküla

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.9. Cefuroxime sodium[16] (NAP) - PSUSA/00000615/202204

Applicant(s): various

PRAC Lead: Maia Uusküla

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.10. Certoparin (NAP) - PSUSA/00000625/202204

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.11. Epoprostenol (NAP) - PSUSA/00001242/202203

Applicant(s): various

PRAC Lead: Ronan Grimes

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.12. Estradiol, norethisterone (NAP) - PSUSA/00001278/202203

Applicant(s): various

PRAC Lead: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

[16] All routes of administration except intracameral use

6.3.13. Ethinylestradiol, levonorgestrel (NAP) - PSUSA/00001309/202204

Applicant(s): various

PRAC Lead: Marie Louise Schougaard Christiansen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.14. Etoricoxib (NAP) - PSUSA/00001334/202203

Applicant(s): various

PRAC Lead: Inês Ribeiro-Vaz

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.15. Fentanyl [17] [18] (NAP) - PSUSA/00001370/202204

Applicant(s): various

PRAC Lead: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.16. Gentamicin[19] (NAP) - PSUSA/00010628/202203

Applicant(s): various

PRAC Lead: Valentina Di Giovanni

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.17. Glucosamine (NAP) - PSUSA/00001539/202203

Applicant(s): various

PRAC Lead: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.18. Human rabies immunoglobulin (NAP) - PSUSA/00001639/202204

Applicant(s): various

[17] Transdermal patches and solution for injection only
[18] Nationally authorised product(s) only
[19] Implant(s) only

PRAC Lead: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.19. Isotretinoin[20] (NAP) - PSUSA/00010488/202205

Applicant(s): various

PRAC Lead: Krõõt Aab

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.20. Itraconazole (NAP) - PSUSA/00001798/202203

Applicant(s): various

PRAC Lead: Marie Louise Schougaard Christiansen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.21. Ivermectin[21] (NAP) - PSUSA/00010377/202204

Applicant(s): various

PRAC Lead: Nathalie Gault

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.22. Lamivudine, tenofovir disoproxil (NAP) - PSUSA/00010751/202203

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.23. Lidocaine, prilocaine[22] (NAP) - PSUSA/00001867/202203

Applicant(s): various

PRAC Lead: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

[20] Oral formulation(s) only
[21] Systemic use only
[22] Centrally authorised product(s) excluded

6.3.24. Linezolid (NAP) - PSUSA/00001888/202204

Applicant(s): various

PRAC Lead: Anna Mareková

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.25. Methoxyflurane (NAP) - PSUSA/00010484/202205

Applicant(s): various

PRAC Lead: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.26. Methyl salicylate (NAP); menthol, methyl salicylate (NAP); menthol, methyl salicylate, camphor (NAP); methyl salicylate, camphor (NAP); methyl salicylate, menthol, camphor, tocopherol (NAP); methyl salicylate, camphor, menthol, turpentine (essence, oil) (NAP); methyl salicylate, menthol, camphor, hydroxyethyl salicylate (NAP); methyl salicylate, menthol, camphor, hydroxyethyl salicylate, benzyl nicotinate (NAP) - PSUSA/00010658/202204

Applicant(s): various

PRAC Lead: Inês Ribeiro-Vaz

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.27. Moclobemide (NAP) - PSUSA/00002079/202204

Applicant(s): various

PRAC Lead: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.28. Mometasone furoate, olopatadine (NAP) - PSUSA/00010957/202204

Applicant(s): various

PRAC Lead: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.29. Mupirocin (NAP) - PSUSA/00002096/202203

Applicant(s): various

PRAC Lead: Polona Golmajer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.30. Nefopam (NAP) - PSUSA/00002131/202203

Applicant(s): various

PRAC Lead: Nikica Mirošević Skvrce

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.31. Omeprazole (NAP) - PSUSA/00002215/202204

Applicant(s): various

PRAC Lead: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.32. Ozenoxacin (NAP) - PSUSA/00010651/202205

Applicant(s): various

PRAC Lead: Monica Martinez Redondo

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.33. Sertraline (NAP) - PSUSA/00002696/202203

Applicant(s): various

PRAC Lead: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.34. Sulprostone (NAP) - PSUSA/00002828/202204

Applicant(s): various

PRAC Lead: Nathalie Gault

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.35. Tretinoin[23] (NAP) - PSUSA/00003015/202203

Applicant(s): various

PRAC Lead: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.36. Triptorelin (NAP) - PSUSA/00003048/202203

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.37. Vinorelbine (NAP) - PSUSA/00003124/202204

Applicant(s): various

PRAC Lead: Eva Jirsová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.4. Follow-up to PSUR/PSUSA procedures

6.4.1. Cabozantinib - CABOMETYX (CAP) - EMEA/H/C/004163/LEG 007

Applicant: Ipsen Pharma

PRAC Rapporteur: Menno van der Elst

Scope: Causality assessment of pneumonia cases already reported as confounded by the MAH as well as of any newly reported cases, as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00010180/202111) adopted in July 2022

Action: For adoption of advice to CHMP

6.4.2. Cabozantinib - COMETRIQ (CAP) - EMEA/H/C/002640/LEG 022

Applicant: Ipsen Pharma

PRAC Rapporteur: Menno van der Elst

Scope: Causality assessment of pneumonia cases already reported as confounded by the MAH as well as of any newly reported cases as requested in the conclusions of the PSUR

[23] Oral formulation(s) only

single assessment (PSUSA) procedure (PSUSA/00010180/202111) adopted in July 2022

Action: For adoption of advice to CHMP

6.4.3. Capecitabine - XELODA (CAP) - EMEA/H/C/000316/LEG 035

Applicant: CHEPLAPHARM Arzneimittel GmbH

PRAC Rapporteur: Martin Huber

Scope: Comprehensive review concerning dihydropyrimidine dehydrogenase (DPD) phenotyping as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00000531/201804) adopted in January 2019

Action: For adoption of advice to CHMP

6.4.4. Lopinavir, ritonavir - ALUVIA (Art 58[24]) - EMEA/H/W/000764/LEG 034

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Nathalie Gault

Scope: Comprehensive reviews of available evidence to fully characterize the risk of QT prolongation, as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (EMEA/H/W/000764/PSUV/0115) adopted in June 2022

Action: For adoption of advice to CHMP

6.4.5. Lopinavir, ritonavir - KALETRA (CAP) - EMEA/H/C/000368/LEG 124

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Nathalie Gault

Scope: Comprehensive reviews of available evidence to fully characterize the risk of QT prolongation, as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00001905/202109) adopted in June 2022

Action: For adoption of advice to CHMP

6.4.6. Methotrexate - NORDIMET (CAP) - EMEA/H/C/003983/LEG 005

Applicant: Nordic Group B.V.

PRAC Rapporteur: Martin Huber

Scope: Comprehensive reviews of available evidence in relation to the mechanism of genotoxicity of methotrexate, as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00002014/202110) concluded in June 2022

Action: For adoption of advice to CHMP

[24] Article 58 of Regulation (EC) No 726/2004 allows the Committee for Medicinal Products for Human Use (CHMP) to give opinions, in co-operation with the World Health Organisation (WHO) on medicinal products for human use that are intended exclusively for markets outside of the European Union (EU).

6.4.7. Methotrexate - JYLAMVO (CAP) - EMEA/H/C/003756/LEG 004

Applicant: Therakind (Europe) Limited

PRAC Rapporteur: Martin Huber

Scope: Comprehensive reviews of available evidence in relation to the mechanism of genotoxicity of methotrexate, as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00002014/202110) concluded in June 2022

Action: For adoption of advice to CHMP

6.5. Variation procedure(s) resulting from PSUSA evaluation

6.5.1. Alglucosidase alfa - MYOZYME (CAP) - EMEA/H/C/000636/II/0092

Applicant: Genzyme Europe BV

PRAC Rapporteur: Nathalie Gault

Scope: Update of sections 4.6 and 5.3 of the SmPC in order to update information on pregnancy, lactation and fertility following the request by PRAC in the AR for MEA/024.17 and MEA/025.17 and in the PSUR single assessment (PSUSA) procedure (PSUSA/00000086/202109) concluded in June 2022. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information

Action: For adoption of PRAC Assessment Report

6.5.2. Daratumumab - DARZALEX (CAP) - EMEA/H/C/004077/II/0063, Orphan

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Inês Ribeiro-Vaz

Scope: Update of section 4.4 of the SmPC in order to update the warnings and precautions for myocardial infarction and ocular events following PSUR single assessment (PSUSA) procedure (PSUSA/00010498/202111) concluded in June 2022, based on the cumulative review of the relevant cases retrieved from the MAH's global safety database, clinical database, epidemiological evaluation and literature review. The package leaflet is updated accordingly

Action: For adoption of PRAC Assessment Report

6.6. Expedited summary safety reviews[25]

6.6.1. Coronavirus (COVID-19) vaccine (inactivated, adjuvanted, adsorbed) - COVID-19 VACCINE (INACTIVATED, ADJUVANTED) VALNEVA (CAP) - EMEA/H/C/006019/MEA 009.3

Applicant: Valneva Austria GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Fourth expedited summary safety report (SSR) for covid-19 vaccine (inactivated, adjuvanted) Valneva during the coronavirus disease (COVID-19) pandemic

Action: For adoption of advice to CHMP

7. Post-authorisation safety studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)[26]

7.1.1. Axicabtagene ciloleucel - YESCARTA (CAP) - EMEA/H/C/PSA/S/0087.1

Applicant: Kite Pharma EU B.V., ATMP[27]

PRAC Rapporteur: Anette Kirstine Stark

Scope: Substantial amendment to a protocol for a long-term, non-interventional study of recipients of Yescarta for treatment of relapsed or refractory Diffuse Large B-cell Lymphoma and Primary Mediastinal B-cell Lymphoma

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.2. Blinatumomab - BLINCYTO (CAP) - EMEA/H/C/PSA/S/0096

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Eva Jirsová

Scope: Substantial amendment to a protocol for an observational PASS to describe the long-term safety profile of first-relapse B-precursor acute lymphocytic leukemia (ALL) paediatric patients who have been treated with blinatumomab or chemotherapy prior to undergoing haemopoietic stem cell transplant

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.3. Velmanase alfa - LAMZEDE (CAP) - EMEA/H/C/PSA/S/0094

Applicant: Chiesi Farmaceutici S.p.A.

[25] Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC
[26] In accordance with Article 107n of Directive 2001/83/EC
[27] Advanced therapy medicinal product

PRAC Rapporteur: Jan Neuhauser

Scope: Substantial amendment to a protocol for study: THE ALPHA-MANNOSIDOSIS REGISTRY: a multi-centre, multi-country, non-interventional, prospective cohort, in alpha-mannosidosis patients to evaluate the long-term effectiveness and safety profile of treatment with Lamzede under conditions of routine clinical care and to characterize the entire alpha-mannosidosis population, including variability of clinical manifestation, progression and natural history

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.4. Lisocabtagene maraleucel - BREYANZI (CAP) - EMEA/H/C/PSP/S/0098.1

Applicant: Bristol-Myers Squibb Pharma EEIG, ATMP[28]

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: MAH's response to PSP/0098 [Submission of a non-interventional PASS of patients treated with commercially available liso-cel (lisocabtagene maraleucel) for relapsed/refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and follicular lymphoma Grade 3B after 2 or more lines of systemic therapy in the postmarketing setting to characterize the incidence and severity of selected adverse drug reactions (ADRs), as outlined in the SmPC, and to monitor for potential clinically important adverse events (AEs) that have not yet been identified as part of the liso-cel safety profile] as per the request to supplementary information (RSI) adopted in July 2022

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.5. Lonafarnib - ZOKINVY (CAP) - EMEA/H/C/PSP/S/0102

Applicant: EigerBio Europe Limited

PRAC Rapporteur: Adam Przybylkowski

Scope: Prospective observational study to evaluate the long-term safety and effectiveness of lonafarnib treatment among patients with Hutchinson-Gilford Progeria Syndrome (HGPS) or a processing deficient progeroid laminopathy (PDPL) in real-world clinical care settings

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.6. Rurioctocog alfa pegol - ADYNOVI (CAP) - EMEA/H/C/PSA/S/0095

Applicant: Baxalta Innovations GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Substantial amendment to a protocol for study: evaluation of long-term safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, rurioctocog alfa pegol) in adults and adolescents ⩾12 years of age with haemophilia A

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

[28] Advanced therapy medicinal product

7.2. Protocols of PASS non-imposed in the marketing authorisation(s)[29]

7.2.1. Anifrolumab - SAPHNELO (CAP) - EMEA/H/C/004975/MEA 002

Applicant: AstraZeneca AB

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Protocol for study D3461R00046: a non-interventional cohort study and meta-analysis on the risk of malignancy in systemic lupus erythematosus patients receiving anifrolumab

Action: For adoption of advice to CHMP

7.2.2. Avacopan - TAVNEOS (CAP) - EMEA/H/C/005523/MEA 002.1

Applicant: Vifor Fresenius Medical Care Renal Pharma France

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: MAH's response to MEA 002 [protocol and feasibility report for study CS-AVA-2022-0016 (listed as category 3 study in the RMP): avacopan real world evidence in anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis - characterisation of the safety concerns of avacopan (i.e. liver injury, serious infections, malignancies and cardiovascular events) beyond the known safety profile based on clinical trial data limited to 52 weeks of exposure] as per request for supplementary information (RSI) adopted in July 2022

Action: For adoption of advice to CHMP

7.2.3. Ciltacabtagene autoleucel - CARVYKTI (CAP) - EMEA/H/C/005095/MEA 007

Applicant: Janssen-Cilag International NV, ATMP[30]

PRAC Rapporteur: Jo Robays

Scope: Protocol for study PCSONCA0014: a survey to evaluate the effectiveness of the ciltacabtagene autoleucel HCP Educational Program and the Product Handling Training

Action: For adoption of advice to CAT and CHMP

7.2.4. Coronavirus (COVID-19) vaccine (inactivated, adjuvanted, adsorbed) - COVID-19 VACCINE (INACTIVATED, ADJUVANTED) VALNEVA (CAP) - EMEA/H/C/006019/MEA 001

Applicant: Valneva Austria GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Protocol for pregnancy exposure registry (C-VIPER): a study to estimate the risk of the most common obstetric outcomes, i.e. pregnancy losses, placentation disorders, gestational diabetes, premature delivery, and COVID-19, neonatal outcomes, i.e. congenital

[29] In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004
[30] Advanced therapy medicinal product

anomalies, low birth weight for gestational age, neonatal intensive care unit admission, and COVID-19, among pregnant women exposed to COVID-19 Vaccine (inactivated, adjuvanted) Valneva from 30 days prior to the first day of the last menstrual period (LMP) to end of pregnancy and their offspring relative to a matched unexposed reference group

Action: For adoption of advice to CHMP

7.2.5. Coronavirus (COVID-19) vaccine (inactivated, adjuvanted, adsorbed) - COVID-19 VACCINE (INACTIVATED, ADJUVANTED) VALNEVA (CAP) - EMEA/H/C/006019/MEA 002

Applicant: Valneva Austria GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Protocol for a post-authorisation safety study to estimate the incidence of adverse events of special interest (AESIs), including the potential risk of vaccine associated enhanced disease (VAED) and vaccine associated respiratory disease (VAERD), that are medically attended following the administration of COVID-19 Vaccine (inactivated, adjuvanted) Valneva in the real-world immunisation setting

Action: For adoption of advice to CHMP

7.2.6. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 065.1

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: MAH's response to MEA 065 [submission of a revised protocol for study mRNA-1273-P910: clinical course, outcomes and risk factors of myocarditis following administration of mRNA-1273 alongside with the first interim report of the study] as per request for supplementary information (RSI) adopted in July 2022

Action: For adoption of advice to CHMP

7.2.7. Eptinezumab - VYEPTI (CAP) - EMEA/H/C/005287/MEA 004.1

Applicant: H. Lundbeck A/S

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: MAH's response to MEA 004 [protocol for study 19756N: a long-term cardiovascular safety and real-world use of eptinezumab - an observational, historical cohort study of patients initiating eptinezumab in routine clinical practice] as per request for supplementary information (RSI) adopted in June 2022

Action: For adoption of advice to CHMP

7.2.8. Fremanezumab - AJOVY (CAP) - EMEA/H/C/004833/MEA 005.4

Applicant: TEVA GmbH

PRAC Rapporteur: Kirsti Villikka

Scope: Submission of a protocol for study TV48125-MH-40217: a long-term observational, retrospective cohort study to evaluate the safety, including cardiovascular safety, of fremanezumab in patients with migraine in routine clinical practice in the United States and Europe (Non-Interventional Phase IV Study)

Action: For adoption of advice to CHMP

7.2.9. Lusutrombopag - MULPLEO (CAP) - EMEA/H/C/004720/MEA 002.3

Applicant: Shionogi B.V.

PRAC Rapporteur: Mari Thorn

Scope: Substantial amendment to an agreed protocol for study VV-REG-090246 hepatic safety of lusutrombopag Shionogi in patients with Child Pugh Class C liver disease

Action: For adoption of advice to CHMP

7.2.10. Naltrexone hydrochloride, bupropion hydrochloride - MYSIMBA (CAP) - EMEA/H/C/003687/MEA 003.14

Applicant: Orexigen Therapeutics Ireland Limited

PRAC Rapporteur: Martin Huber

Scope: MAH's response to MEA 003.12 [protocol for study NB-451: an observational retrospective drug utilisation study (DUS) of Mysimba (naltrexone hydrochloride/bupropion hydrochloride) in Europe and the United States to describe the demographic and baseline characteristics of users of Mysimba (naltrexone hydrochloride/bupropion hydrochloride), evaluate patterns of Mysimba (naltrexone hydrochloride/bupropion hydrochloride) initiation and use] as per request for supplementary information (RSI) adopted in July 2022

Action: For adoption of advice to CHMP

7.2.11. Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/MEA 014.6

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Amendment to a previously agreed protocol for study A3921321 (listed as category 3 study in the RMP): a Post-Authorisation Safety Study (PASS) of the Utilisation and Prescribing Patterns of Xeljanz (tofacitinib) in two European Countries Using Administrative Claims Databases and National Registries for assessment

Action: For adoption of advice to CHMP

7.2.12. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 009

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Amendment to a previously agreed protocol for study C4591011: active safety surveillance of the Pfizer-BioNTech COVID-19 Vaccine in the United States (US) Department

of Defense (DoD) Population following emergency use authorization to assess whether individuals in the US DoD Military Health System (MHS) experience increased risk of safety events of interest, including myocarditis and pericarditis

Action: For adoption of advice to CHMP

7.2.13. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/MEA 013.2

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: MAH's response to MEA 013.1 [revised protocol for study P20-390: a cohort study of long-term safety of upadacitinib in the treatment of atopic dermatitis in Denmark and Sweden] as per request for supplementary information (RSI) adopted in July 2022

Action: For adoption of advice to CHMP

7.2.14. Vosoritide - VOXZOGO (CAP) - EMEA/H/C/005475/MEA 005.2

Applicant: BioMarin International Limited

PRAC Rapporteur: Zane Neikena

Scope: Substantial amendment to a previously agreed protocol for study BMN111-603: a multicenter, non-interventional study to evaluate long-term safety in patients with achondroplasia treated with Voxzogo (vosoritide)

Action: For adoption of advice to CHMP

7.3. Results of PASS imposed in the marketing authorisation(s)[31]

None

7.4. Results of PASS non-imposed in the marketing authorisation(s)[32]

7.4.1. Delamanid - DELTYBA (CAP) - EMEA/H/C/002552/II/0061, Orphan

Applicant: Otsuka Novel Products GmbH

PRAC Rapporteur: Jo Robays

Scope: Update of sections 4.2 and 4.4 of the SmPC in order to update treatment duration based on final results from EU PASS (protocol no. 242-12-402), listed as a category 3 study in the RMP. This is a "A Multicentre, EU-wide, Non-Interventional Post-Authorisation Study to Assess the Safety and Usage of Delamanid in Routine Medical Practice in Multidrug-Resistant Tuberculosis (MDR-TB) Patients". This treatment registry was for monitoring and documenting Deltyba use in routine medical practice and aimed to assess compliance with the recommendations in the authorised product information when prescribed as part of an appropriate combination regimen (ACR) for the treatment of MDR-TB. The package leaflet is

[31] In accordance with Article 107p-q of Directive 2001/83/EC
[32] In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013

updated accordingly. The RMP version 4.2 has also been submitted. In addition, the MAH took the opportunity to update Annex II section D of the SmPC

Action: For adoption of PRAC Assessment Report

7.4.2. Idelalisib - ZYDELIG (CAP) - EMEA/H/C/003843/II/0056

Applicant: Gilead Sciences Ireland UC

PRAC Rapporteur: Martin Huber

Scope: Submission of the final report from study GS-EU-313-4172 listed as a category 3 study in the RMP. This is a non-interventional study to assess the safety profile of idelalisib in patients with refractory follicular lymphoma (FL) with primary objective to assess the overall safety profile of idelalisib monotherapy in patients with refractory FL

Action: For adoption of PRAC Assessment Report

7.4.3. Liraglutide - SAXENDA (CAP) - EMEA/H/C/003780/II/0034

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Menno van der Elst

Scope: Submission of the final report from study NN8022-4246 listed as a category 3 study in the RMP. This is an in-market utilisation non-interventional PASS of liraglutide used for weight management in the UK using the clinical practice research datalink (CPRD) Primary Care Database. The RMP version 33.0 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.4. Pegfilgrastim - NEULASTA (CAP) - EMEA/H/C/000420/II/0121

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Submission of the final report from PASS study 20170701 listed as a category 3 study in the RMP. This is a cross-sectional survey study to Assess the Effectiveness of the Neulasta Patient Alert Card and to Measure Medication Errors Related to the Use of the Neulasta On-Body Injector. The RMP version 9.0 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.5. Talimogene laherparepvec - IMLYGIC (CAP) - EMEA/H/C/002771/II/0056

Applicant: Amgen Europe B.V., ATMP[33]

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Submission of the final report from study 20120139 listed as a category 3 study in the RMP in order to fulfil MEA/004. This is a multicenter, observational registry study to evaluate the survival and long-term safety of subjects who previously received talimogene

[33] Advanced therapy medicinal product

laherparepvec in Amgen or BioVEX sponsored clinical trials

Action: For adoption of PRAC Assessment Report

7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation

7.5.1. Adalimumab - IMRALDI (CAP) - EMEA/H/C/004279/MEA 003.1

Applicant: Samsung Bioepis NL B.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Second interim report of the safety surveillance programme using the Register for Antirheumatic Therapies in Sweden (ARTIS): a national prospective, observational, uncontrolled cohort study to evaluate the risk of selected adverse events (AEs) in rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) and other rheumatic disease patients treated with adalimumab

Action: For adoption of advice to CHMP

7.5.2. Adalimumab - IMRALDI (CAP) - EMEA/H/C/004279/MEA 004.1

Applicant: Samsung Bioepis NL B.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Second interim report of the safety surveillance programme using the Spanish Registry for Adverse Events for Biological Therapy in Rheumatic Diseases (BIOBASASER)

Action: For adoption of advice to CHMP

7.5.3. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 003.8

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: MAH's response to MEA 003.6 [Fifth interim report for a study (listed as a category 3 study in the RMP): a post authorisation safety of Spikevax (elasomeran) in the US - an enhanced pharmacovigilance study to provide additional evaluation of adverse events of special interest (AESI) and emerging validated safety signals [P903] as per request for supplementary information (RSI) adopted in July 2022

Action: For adoption of advice to CHMP

7.5.4. Human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - CERVARIX (CAP) - EMEA/H/C/000721/II/0117

Applicant: GlaxoSmithkline Biologicals SA

PRAC Rapporteur: Jean-Michel Dogné

Scope: Submission of the interim report from study EPI-HPV-099 (217743). This is an observational, retrospective database post-authorisation safety study (PASS) assessing

trends and changes over time in incidence of anal cancer and feasibility for a case-control study in European countries that introduced Cervarix in their National Immunisation Programme. The study was set up to address the missing information on the impact and effectiveness of Cervarix against anal lesions and cancer in the Cervarix RMP. The RMP version 26 has also been submitted

Action: For adoption of advice to CHMP

7.5.5. Nivolumab - OPDIVO (CAP) - EMEA/H/C/003985/MEA 008.10

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Sixth annual interim report for study CA209234 (listed as a category 3 study in the RMP): a PASS exploring the pattern of use, safety, and effectiveness of nivolumab in routine oncology practice [final clinical study report (CSR) expected in December 2024]

Action: For adoption of advice to CHMP

7.5.6. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 001.5

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: Fourth interim report for study OP0005: a European non-interventional PASS to study the adherence to the risk minimisation measures (RMMs) in the product information by estimating the compliance with contraindications and target indication(s) amongst incident romosozumab users, and analysing the utilisation pattern using the EU-adverse drug reactions (EU-ADR) Alliance

Action: For adoption of advice to CHMP

7.5.7. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 002.5

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: Fourth interim report for study OP0004: a European non-interventional PASS to evaluate potential differences in terms of serious cardiovascular adverse events between romosozumab and currently available therapies used in comparable patients in real-world conditions using the EU-adverse drug reactions (EU-ADR) Alliance

Action: For adoption of advice to CHMP

7.5.8. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.3

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: Second interim report for study OP0006: a European non-interventional PASS to evaluate potential differences in terms of serious infection between romosozumab and

currently available therapies used in comparable patients in real-world conditions using the EU-adverse drug reactions (EU-ADR) Alliance [final study results expected in December 2024]

Action: For adoption of advice to CHMP

7.5.9. Siponimod - MAYZENT (CAP) - EMEA/H/C/004712/MEA 003.1

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Maria del Pilar Rayon

Scope: First annual interim report for study CBAF312A2403: a post-authorisation safety study for assessment of pregnancy outcomes in patients treated with Mayzent (siponimod): an OTIS observational pregnancy surveillance study

Action: For adoption of advice to CHMP

7.5.10. Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/MEA 013.5

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: First interim report for study A3921344 (listed as category 3 study in the RMP): an active surveillance, post-authorisation study to characterize the safety of tofacitinib in patients with moderately to severely active ulcerative colitis in the real-world setting using data from the Swedish Quality Register for Inflammatory Bowel Disease

Action: For adoption of advice to CHMP

7.5.11. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 011.6

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Interim report for study C4591010: a post-approval active surveillance safety study to monitor real-world safety of Comirnaty (tozinameran) vaccine in the EU

Action: For adoption of advice to CHMP

7.5.12. Ustekinumab - STELARA (CAP) - EMEA/H/C/000958/MEA 044.15

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Rhea Fitzgerald

Scope: MAH's response to MEA 044.14 [Fourth interval safety registry for study CNTO1275PSO4056: an observational PASS of ustekinumab in the treatment of paediatric patients aged 12 years and older with moderate to severe plaque psoriasis (adolescent registry)] as per request for supplementary information (RSI) adopted in July 2022

Action: For adoption of advice to CHMP

7.6. Others

7.6.1. Alemtuzumab - LEMTRADA (CAP) - EMEA/H/C/003718/ANX 009.1

Applicant: Sanofi Belgium

PRAC Rapporteur: Anette Kirstine Stark

Scope: Feasibility report for a non-interventional PASS to investigate the risk in mortality of multiple sclerosis (MS) patients treated with alemtuzumab relative to comparable other MS patients using other DMTs (disease modifying therapies)

Action: For adoption of advice to CHMP

7.6.2. Alemtuzumab - LEMTRADA (CAP) - EMEA/H/C/003718/ANX/010.4

Applicant: Sanofi Belgium

PRAC Rapporteur: Anette Kirstine Stark

Scope: Response to questions about the feasibility report of the non-interventional PASS to investigate drug utilisation and safety monitoring patterns for LEMTRADA (alemtuzumab) [MAH's response to PSA/S/0088]

Action: For adoption of advice to CHMP

7.6.3. Darolutamide - NUBEQA (CAP) - EMEA/H/C/004790/REC 004.1

Applicant: Bayer AG

PRAC Rapporteur: Jan Neuhauser

Scope: MAH's response to REC 004 [submission of an addendum to the final clinical report for study (17712): efficacy and safety study of darolutamide (ODM-201) in men with high-risk non-metastatic castration-resistant prostate cancer (ARAMIS)] as per request for supplementary information (RSI) adopted in July 2022

Action: For adoption of advice to CHMP

7.6.4. Natalizumab - TYSABRI (CAP) - EMEA/H/C/000603/MEA 071.2

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: MAH's response to MEA 071.1 [feasibility assessment report for study OXON 214-04 (listed as a category 3 study in the RMP): an observational study utilising data from EU national multiple sclerosis (MS) registries to estimate the incidence of anti-natalizumab antibody among patients who receive subcutaneous administration (SC) of natalizumab for treatment of relapsing remitting MS in order to investigate immunogenic potential of SC administration (PASS 101MS412) (from X/0116)] as per the request for supplementary information (RSI) adopted in June 2022

Action: For adoption of advice to CHMP

7.7. New Scientific Advice

7.8. Ongoing Scientific Advice

7.9. Final Scientific Advice (Reports and Scientific Advice letters)

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments

8.1. Annual reassessments of the marketing authorisation

8.1.1. Asfotase alfa - STRENSIQ (CAP) - EMEA/H/C/003794/S/0059 (without RMP)

Applicant: Alexion Europe SAS

PRAC Rapporteur: Rhea Fitzgerald

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.2. Cerliponase alfa - BRINEURA (CAP) - EMEA/H/C/004065/S/0038 (without RMP)

Applicant: BioMarin International Limited

PRAC Rapporteur: Mari Thorn

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.3. Lomitapide - LOJUXTA (CAP) - EMEA/H/C/002578/S/0052 (without RMP)

Applicant: Amryt Pharmaceuticals DAC

PRAC Rapporteur: Menno van der Elst

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.4. Mecasermin - INCRELEX (CAP) - EMEA/H/C/000704/S/0078 (without RMP)

Applicant: Ipsen Pharma

PRAC Rapporteur: Kirsti Villikka

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.5. Odevixibat - BYLVAY (CAP) - EMEA/H/C/004691/S/0008 (without RMP)

Applicant: Albireo

PRAC Rapporteur: Adam Przybylkowski

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.2. Conditional renewals of the marketing authorisation

8.2.1. Coronavirus (COVID-19) vaccine (Ad26.COV2-S, recombinant) - JCOVDEN (CAP) - EMEA/H/C/005737/R/0063 (without RMP)

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.2. Delamanid - DELTYBA (CAP) - EMEA/H/C/002552/R/0062 (without RMP)

Applicant: Otsuka Novel Products GmbH

PRAC Rapporteur: Jo Robays

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.3. Dostarlimab - JEMPERLI (CAP) - EMEA/H/C/005204/R/0017 (without RMP)

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Inês Ribeiro-Vaz

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.4. Parathyroid hormone - NATPAR (CAP) - EMEA/H/C/003861/R/0046 (without RMP)

Applicant: Takeda Pharmaceuticals International AG

PRAC Rapporteur: Rhea Fitzgerald

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.5. Pemigatinib - PEMAZYRE (CAP) - EMEA/H/C/005266/R/0007 (without RMP)

Applicant: Incyte Biosciences Distribution B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3. Renewals of the marketing authorisation

8.3.1. Adalimumab - HEFIYA (CAP) - EMEA/H/C/004865/R/0038 (without RMP)

Applicant: Sandoz GmbH

PRAC Rapporteur: Ulla Wändel Liminga

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.2. Adalimumab - HYRIMOZ (CAP) - EMEA/H/C/004320/R/0037 (without RMP)

Applicant: Sandoz GmbH

PRAC Rapporteur: Ulla Wändel Liminga

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.3. Carmustine - CARMUSTINE OBVIUS (CAP) - EMEA/H/C/004326/R/0009 (with RMP)

Applicant: Obvius Investment B.V

PRAC Rapporteur: Jan Neuhauser

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.4. Erenumab - AIMOVIG (CAP) - EMEA/H/C/004447/R/0024 (with RMP)

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Kirsti Villikka

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.5. Insulin glargine - SEMGLEE (CAP) - EMEA/H/C/004280/R/0040 (without RMP)

Applicant: Viatris Limited

PRAC Rapporteur: Menno van der Elst

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.6. Pemetrexed - PEMETREXED KRKA (CAP) - EMEA/H/C/003958/R/0009 (with RMP)

Applicant: KRKA, d.d., Novo mesto

PRAC Rapporteur: Tiphaine Vaillant

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.7. Sodium zirconium cyclosilicate - LOKELMA (CAP) - EMEA/H/C/004029/R/0027 (without RMP)

Applicant: AstraZeneca AB

PRAC Rapporteur: Kirsti Villikka

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.8. Trastuzumab - KANJINTI (CAP) - EMEA/H/C/004361/R/0022 (without RMP)

Applicant: Amgen Europe B.V., BREDA

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None

9.2. Ongoing or concluded pharmacovigilance inspections

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

9.3. Others

None

10. Other safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation

None

10.2. Timing and message content in relation to Member States' safety announcements

None

10.3. Other requests

None

10.4. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

11.1.1. Methotrexate (NAP) - DE/H/PSUFU/00002014/202110

Applicant: various

PRAC Lead: Martin Huber

Scope: PRAC consultation on a PSUR follow-up (PSU FU) procedure evaluating comprehensive reviews of available evidence in relation to the mechanism of genotoxicity of methotrexate, as discussed at PRAC and agreed by CMDh following the conclusion of the PSUSA procedure (PSUSA/00002014/202110) concluded in June 2022, on request of Germany

Action: For adoption of advice to Member States

11.2. Other requests

None

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

12.1.1. PRAC membership

Action: For information

12.1.2. Vote by proxy

None

12.2. Coordination with EMA Scientific Committees or CMDh-v

None

12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

None

12.4. Cooperation within the EU regulatory network

12.4.1. Coronavirus (COVID-19) pandemic - update

Action: For discussion

12.5. Cooperation with International Regulators

12.5.1. International Conference on Harmonisation (ICH) E2D(R1) - Post-approval safety data management: definitions and standards for expedited reporting

PRAC lead: Željana Margan Koletić

Action: For discussion

12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee

None

12.7. PRAC work plan

None

12.8. Planning and reporting

None

12.9. Pharmacovigilance audits and inspections

12.9.1. Pharmacovigilance systems and their quality systems

None

12.9.2. Pharmacovigilance inspections

None

12.9.3. Pharmacovigilance audits

None

12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list

12.10.1. Periodic safety update reports

None

12.10.2. Granularity and Periodicity Advisory Group (GPAG)

PRAC lead: Menno van der Elst, Maia Uusküla

Action: For discussion

12.10.3. PSURs repository

None

12.10.4. Union reference date list – consultation on the draft list

Action: For adoption

12.11. Signal management

12.11.1. Signal management – feedback from Signal Management Review Technical (SMART) Working Group

PRAC lead: Menno van der Elst

Action: For discussion

12.12. Adverse drug reactions reporting and additional reporting

12.12.1. Management and reporting of adverse reactions to medicinal products

None

12.12.2. Additional monitoring

None

12.12.3. List of products under additional monitoring – consultation on the draft list

Action: For adoption

12.13. EudraVigilance database

12.13.1. Activities related to the confirmation of full functionality

None

12.14. Risk management plans and effectiveness of risk minimisations

12.14.1. Risk management systems

None

12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations

None

12.15. Post-authorisation safety studies (PASS)

12.15.1. Post-authorisation Safety Studies – imposed PASS

None

12.15.2. Post-authorisation Safety Studies – non-imposed PASS

None

12.16. Community procedures

12.16.1. Referral procedures for safety reasons

None

12.17. Renewals, conditional renewals, annual reassessments

None

12.18. Risk communication and transparency

12.18.1. Public participation in pharmacovigilance

None

12.18.2. Safety communication

None

12.19. Continuous pharmacovigilance

12.19.1. Incident management

None

12.20. Impact of pharmacovigilance activities

12.20.1. Strategy on measuring the impact of pharmacovigilance – PRAC interest group (IG) Impact – PRAC stakeholder engagement regarding risk minimisation

PRAC lead: Liana Gross-Martirosyan

Action: For discussion

12.20.2. Strategy on measuring the impact of pharmacovigilance – PRAC interest group (IG) Impact - review of effectiveness PASS assessed by PRAC between 2016-2021 – final report

Action: For adoption

12.21. Others

12.21.1. EMA pregnancy strategy

Action: For discussion

12.21.2. Good Pharmacovigilance Practice (GVP) Guideline on product or population specific considerations III: pregnancy and breastfeeding

Action: For discussion

12.21.3. Update on IRIS for core regulatory procedures

Action: For discussion

13. Any other business

Next meeting on: 09-12 January 2023

14. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures

(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0

Signals assessment and prioritisation

(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.
The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.
The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)

(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.
RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)

(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation.
PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)

(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections

(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/